SII said, in a statement on Friday that the partnership with IntegriMedical aligns with its vision of ‘Health for All’ and IntegriMedical’s mission to ‘transform healthcare globally’ by providing patient comfort, ensuring increased patient compliance, reducing needle-stick injuries, and enhancing the efficacy of liquid medication via needle-free dispersion.
IntegriMedical has developed a US patented needle-free injection system (N-FIS) that utilises high-velocity jet streams using mechanical power for administering biologics and drugs.
N-FIS will soon be made available in the Indian private market, according to SII.
“At SII, we are constantly seeking opportunities to invest in technologies that align with our mission to make healthcare accessible and affordable for people worldwide. IntegriMedical’s needle-free injection systems (N-FIS) represent a significant advancement in drug delivery and we envision a needle-free solution to deliver vaccines. We believe this could potentially revolutionize the way we administer vaccines, making the process more comfortable for patients and healthcare professionals,” said Adar Poonawalla, CEO, SII.
The collaboration between SII and IntegriMedical will seek to leverage strengths of both companies’ expertise in vaccine manufacturing and innovative drug delivery technology and research capabilities. “Together, the companies aim to expand access to care and improve efficiencies in the global healthcare industry,” according to the statement.Sarvesh Mutha, MD, IntegriMedical said the investment by SII is a testament to the potential of its N-FIS technology and its ability to revolutionise drug delivery.”SII’s expertise in vaccine manufacturing and global distribution will be invaluable as we work towards making our technology more widely accessible to patients worldwide,” he said.
